Parkinson’s puts people at increased risk of complications if they get coronavirus.
The face-to-face support we usually provide is no longer possible. We’re adapting our support to make sure we reach everyone who needs us.
But we can’t do it alone. We need to raise £95,000 every week to guarantee critical support to people over the coming months. Your gift means someone will be on the phone, or online, ready to provide the support that people need, wherever they are, when they need it most.
We're here for you
We have a range of information and support to help you during this challenging time. Our friendly helpline advisers are also available to take your call if you have any concerns, questions, or need further advice.
These projects may be paused. But they still need funding ready to restart as soon as possible
We know in Parkinson’s, mitochondria, the "batteries" that power our cells, don’t always work properly. Researchers believe that finding proteins that can fix the recycling process of these dysfunctioning batteries, could protect dopamine-producing cells from energy failure and death.
In an exciting new project, a team of researchers are investigating how improving this process could pave the way to a new treatment that could slow down or even stop Parkinson’s.
In this world first clinical trial, Professor Sagnik Bhattacharyya and Dr Latha Velayudhan at Kings College London (KCL) will be testing whether cannabidiol (CBD) can treat Parkinson’s psychosis symptoms with the help of the Virtual Biotech.
Dr Susan Duty’s investigating the impact 2 already existing drugs have on increasing a protein known for its protective effects on dopamine-producing brain cells.
We already know the loss of dopamine-producing cells cause symptoms of Parkinson's. Boosting the brain’s supply of a protein (called FGF20) could protect dopamine production. This could provide the potential to slow, stop or reverse Parkinson’s.